GlassScriptPhysician profile
Natarajan Ravendhran
NPI 1821071069
$367,360.08
in general payments reported to CMS, 2019-2025
48 companies · $29K in 2025
The $29K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126K · 2020: $31K · 2021: $32K · 2022: $57K · 2023: $37K · 2024: $55K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $94K · Food and Beverage: $10K · Travel and Lodging: $9,464 · Consulting Fee: $8,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $93,801.50 |
| Food and Beverage | $10,017.75 |
| Travel and Lodging | $9,464.14 |
| Consulting Fee | $8,177.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $219,355.39 | 2019-2025 | Vemlidy, Epclusa, Livdelzi |
| Abbvie INC. | $89,673.63 | 2019-2024 | |
| Madrigal Pharmaceuticals | $43,128.08 | 2024-2025 | Rezdiffra, Resmetirom |
| Siemens Medical Solutions USA, INC. | $5,492.23 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $2,923.80 | 2024-2025 | Iqirvo, Bylvay |
| Celgene Corporation | $1,027.11 | 2019-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $826.76 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $799.31 | 2019-2025 | Entyvio, Gattex |
| Mallinckrodt Hospital Products INC. | $486.84 | 2021-2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $318.93 | 2019-2024 | Ocaliva |
| Pfizer INC. | $281.09 | 2019-2024 | |
| Janssen Biotech, INC. | $274.84 | 2019-2024 | Stelara, Simponi Aria, Remicade |
| Genzyme Corporation | $256.74 | 2022-2024 | |
| Qol Medical, LLC | $252.38 | 2019-2024 | Sucraid, Sucraid |
| Amgen INC. | $216.83 | 2021-2025 |
Show all 45 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natarajan Ravendhran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.